Prof. Dr. med. Arndt Hartmann

Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie

A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients (2018) Häberle L, Erber R, Gaß P, Hein A, Jud S, Langemann H, Rauh C, et al. Conference contribution Transcriptomic and metabolomic profiles in renal cell carcinoma (RCC) tumors reflect ontogeny of RCC subtypes (2018) Fisel P, Buettner F, Reustle A, Klumpp V, Winter S, Rausch S, Hennenlotter J, et al. Conference contribution Loss of EZH2 at tumor invasive front is correlated with higher aggressiveness (2018) Böhm J, Muenzner JK, Caliskan A, Ndreshkjana B, Erlenbach-Wunsch K, Merkel S, Croner RS, et al. Conference contribution Cytoplasmic p21 Mediates 5-Fluorouracil Resistance by Inhibiting Pro-Apoptotic Chk2 (2018) Maiuthed A, Ninsontia C, Erlenbach-Wuensch K, Ndreshkjana B, Muenzner JK, Caliskan A, Ahmed HP, et al. Journal article NAR score as surrogate for disease-free survival in the CAO/ARO/AIO-04 phase 3 rectal cancer trial (2018) Fokas E, Fietkau R, Hartmann A, Hohenberger W, Grützmann R, Ghadimi M, Liersch T, et al. Conference contribution Can local excision be safely recommended in patients with ypT0-2 rectal cancer after chemoradiotherapy? Clinicopathological results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 randomized phase 3 trials (2018) Von Den Gruen MJ, Hartmann A, Fietkau R, Ghadimi M, Liersch T, Stroebel P, Sauer R, et al. Conference contribution Analysis of androgen receptor mRNA expression in urothelial carcinoma of the bladder (2018) Sikic D, Wirtz R, Wach S, Dyrskjot L, Erben P, Bolenz C, Breyer J, et al. Conference contribution A multicenter comparison of PD-L1 protein and mRNA expression in urothelial bladder cancer by immunohistochemistry and RT-qPCR (Checkpoint-Typer(C)): A round robin test by the BRIDGE-Consortium Germany (2018) Eckstein M, Wirtz R, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, et al. Conference contribution A randomised phase II study of Nivolumab plus Ipilimumab versus Standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST) (2018) Ahrens M, Scheich S, Goekbuget N, Boleti E, Gruenwald V, Escudier B, Goebell P, et al. Conference contribution mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants (2018) Eckstein M, Wirtz RM, Gross-Weege M, Breyer J, Otto W, Stoehr R, Sikic D, et al. Journal article